The agent Gemcitabine is a cytostatic belonging to the therapeutic class of pyrimidine antimetabolite.

ATC-Code: L01XX19


Strength is denoted by disposable cap color.

  • Gemcitabine Kabi 200 mg
  • Gemcitabine Kabi 1000 mg
  • Gemcitabine Kabi 2000 mg


  • Locally advanced or metastatic bladder cancer in combination with cisplatin
  • First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin. Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2
  • Locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-ree interval of at least 6 months after platinum-based, first-line therapy
  • Treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy in combination with paclitaxel. Prior chemotherapy should have included an anthracycline unless clinically contraindicated


​1 ml of reconstituted solution contains 38 mg Gemcitabine. Gemcitabine is a white to off-white solid/powder for solution for infusion.

Product Information

Please note that this product may not be available in all countries due to different registration status.

Additionally, approved indications, contraindications, side effects, warnings and all over product characteristics may differ between countries. Therefore, always the text of the nationally registered and approved product information is binding! Furthermore, country specific regulatory considerations affect the information we can provide on our products.

If you require any information please contact your local organization.